The devolved Welsh Government plans to expand the use of an artificial intelligence-powered tool used to spot cancer in biopsy samples, after seeing a 13% increase in pros
Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec
AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US.
Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm
AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed